Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Swedish Orphan Biovitrum AB (publ)
AB
Active
Org 5560389321
Norra Stationsgatan 93 A, 113 64
Stockholm
Wholesale of pharmaceutical and medical goods
·
NACE 4646
Est. 1939 · 86 years old
0 employees
Monitor
Share
Sweden
/
Companies
/
Wholesale of pharmaceutical and medical goods
/
Swedish Orphan Biovitrum AB (publ)
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
21B
15B
10B
5.1B
0B
2021: 12B
12B
2021
2022: 13B (+8% vs 2021)
13B
+8%
2022
2023: 14B (+4% vs 2022)
14B
+4%
2023
2024: 16B (+19% vs 2023)
16B
+19%
2024
2024: 0B (-100% vs 2024)
0B
-100%
2024
EBITDA
SEK millions
5.5B
4.1B
2.7B
1.4B
0B
2021: 4.4B
4.4B
2021
2022: 2.8B (-37% vs 2021)
2.8B
-37%
2022
2023: 2.5B (-11% vs 2022)
2.5B
-11%
2023
2024: 4.2B (+71% vs 2023)
4.2B
+71%
2024
2024: 1.0B (-76% vs 2024)
1.0B
-76%
2024
Income statement
SEK thousands
Item
2024
2024
2023
2022
2021
Revenue
0
16 464 000
13 888 000
13 381 000
12 401 000
Staff expenses
−0
—
—
—
—
EBITDA
1 023 000
4 183 000
2 451 000
2 761 000
4 383 000
Depreciation & amort.
−596 000
—
—
—
—
EBIT
427 000
4 183 000
2 451 000
2 761 000
4 383 000
Net financials
0
−2 670 000
372 000
−373 000
−732 000
Profit before tax
427 000
9 560 000
1 390 000
2 840 000
2 278 000
Tax
−0
−1 979 000
−313 000
−389 000
−488 000
Net profit
427 000
7 581 000
1 077 000
2 451 000
1 790 000
Balance sheet
SEK thousands
Item
2024
2024
2023
2022
2021
Total assets
13 530 000
66 109 000
64 350 000
44 794 000
41 982 000
Equity
0
37 361 000
29 121 000
21 627 000
19 069 000
Long-term debt
0
15 975 000
13 590 000
6 591 000
11 595 000
Short-term debt
0
12 772 000
16 934 000
12 667 000
7 548 000
Total debt
0
28 747 000
30 524 000
19 258 000
19 143 000
Financial ratios
5-year trend
EBITDA margin
>999 %
This company
15,8 %
Market median
This company
Market median
>999% above market
2021
2024
Equity ratio
0,0 %
This company
38,2 %
Market median
This company
Market median
100% below market
2021
2024
Return on equity
—
This company
18,4 %
Market median
This company
Market median
2021
2024
Net profit margin
>999 %
This company
8,1 %
Market median
This company
Market median
>999% above market
2021
2024
Asset turnover
0,00×
This company
1,12×
Market median
This company
Market median
100% below market
2021
2024
Debt / equity
—
This company
0,62×
Market median
This company
Market median
2021
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
More on Swedish Orphan Biovitrum AB (publ)
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
